A Smart Self-Immobilization Magnetic Resonance Contrast Agent for Delayed Tumor Imaging In Vivo.

Area of Science:

• Biomedical Imaging
• Nanotechnology
• Chemistry

Background:

• Improving magnetic resonance imaging (MRI) probe sensitivity for tumor detection is crucial.
• Current small-molecule MRI probes face challenges with tumor-specific accumulation and probe washout.

Purpose of the Study:

• To develop an enzyme-responsive, self-immobilizing small-molecule MRI probe for high-sensitivity tumor imaging.
• To enhance probe retention at the tumor site and improve MRI signal.

Main Methods:

• Designed P-QM-Gd, a probe activated by membrane-bound alkaline phosphatase (ALP).
• Enzymatic activation generates intermediates that covalently conjugate gadolinium complexes to tumor cell membranes.
• Evaluated probe performance in subcutaneous and orthotopic tumor models in mice.

Main Results:

• Enzymatic self-immobilization increased longitudinal relaxivity (r1) from 7.35 to 13.15 mM⁻¹s⁻¹.
• P-QM-Gd demonstrated rapid tumor uptake, efficient covalent labeling, and >60% MR contrast enhancement.
• Enabled precise visualization of small tumors (∼1.3 mm) up to 24 hours post-injection.

Conclusions:

• P-QM-Gd overcomes limitations of traditional MRI probes through enzymatic self-immobilization.
• Offers a promising strategy for high-sensitivity, high-spatial resolution delayed tumor MRI.
• Effective for early-stage lesion detection and improved cancer diagnosis.